Your email has been successfully added to our mailing list.

×
0 -0.00212765957446817 -0.00212765957446817 -0.0134751773049646 -0.00851063829787241 -0.00851063829787241 -0.00851063829787241 -0.00851063829787241
Stock impact report

Silence Therapeutics reports Q3 results [Seeking Alpha]

Silence Therapeutics Plc - American Depository Share (SLN) 
Company Research Source: Seeking Alpha
Net loss for the three ended September 30, 2024, was £27.0 million, or 19.1 pence basic and diluted net loss per share. More on Silence Therapeutics Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' Silence: Additional siRNA Drug Data Leads To Next Stages Of Development Seeking Alpha's Quant Rating on Silence Therapeutics Historical earnings data for Silence Therapeutics Financial information for Silence Therapeutics Recommended For You Comments More Trending News Show less Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SLN alerts

from News Quantified
Opt-in for
SLN alerts

from News Quantified